表紙
市場調査レポート

慢性尋常性乾癬:パイプライン分析

Chronic Plaque Psoriasis - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 253634
出版日 ページ情報 英文 125 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
慢性尋常性乾癬:パイプライン分析 Chronic Plaque Psoriasis - Pipeline Review, H2 2015
出版日: 2015年07月31日 ページ情報: 英文 125 Pages
概要

慢性尋常性乾癬は、体や頭皮の伸筋表面上の、境界が明瞭な紅斑、鱗屑を特徴とする慢性炎症性皮膚疾患です。銀白色の鱗屑で覆われた肌の紅斑、乾燥肌、ひび割れなどの症状が見られます。治療には、外用副腎皮質ステロイド、外用レチノイド、ビタミンD類似体が含まれます。

当レポートでは、慢性尋常性乾癬に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

慢性尋常性乾癬の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

治療薬の開発に従事している企業

  • AbGenomics International, Inc.
  • Almirall, S.A.
  • Boehringer Ingelheim GmbH
  • Cellceutix Corporation
  • Coherus BioSciences, Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • 田辺三菱製薬
  • Novartis AG
  • OPKO Health, Inc.
  • Pfizer Inc.
  • Sandoz International GmbH
  • Sun Pharma Advanced Research Company Ltd.
  • 武田薬品工業
  • UCB S.A.
  • XenoPort, Inc.

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • AbGn-168H
  • adalimumab biosimilar
  • adalimumab biosimilar
  • baricitinib
  • BI-655066
  • C-82
  • certolizumab pegol
  • CJM-112
  • COVA-322
  • dimethyl fumarate
  • etanercept biosimilar
  • etanercept biosimilar
  • etanercept biosimilar
  • GSK-2831781
  • ixekizumab
  • KM-133
  • lunacalcipol
  • MT-1303
  • namilumab
  • orilotimod potassium
  • tildrakizumab
  • tofacitinib
  • XP-23829

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC6862IDB

Summary

Global Markets Direct's, 'Chronic Plaque Psoriasis - Pipeline Review, H2 2015', provides an overview of the Chronic Plaque Psoriasis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Plaque Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Plaque Psoriasis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Chronic Plaque Psoriasis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Chronic Plaque Psoriasis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Chronic Plaque Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Chronic Plaque Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Chronic Plaque Psoriasis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Chronic Plaque Psoriasis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Chronic Plaque Psoriasis Overview
  • Therapeutics Development
    • Pipeline Products for Chronic Plaque Psoriasis - Overview
    • Pipeline Products for Chronic Plaque Psoriasis - Comparative Analysis
  • Chronic Plaque Psoriasis - Therapeutics under Development by Companies
  • Chronic Plaque Psoriasis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Chronic Plaque Psoriasis - Products under Development by Companies
  • Chronic Plaque Psoriasis - Companies Involved in Therapeutics Development
    • AbGenomics International, Inc.
    • Almirall, S.A.
    • Boehringer Ingelheim GmbH
    • Cellceutix Corporation
    • Coherus BioSciences, Inc.
    • Eli Lilly and Company
    • GlaxoSmithKline Plc
    • Johnson & Johnson
    • Mitsubishi Tanabe Pharma Corporation
    • Novartis AG
    • OPKO Health, Inc.
    • Pfizer Inc.
    • Sandoz International GmbH
    • Sun Pharma Advanced Research Company Ltd.
    • Takeda Pharmaceutical Company Limited
    • UCB S.A.
    • XenoPort, Inc.
  • Chronic Plaque Psoriasis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AbGn-168H - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • baricitinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BI-655066 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • C-82 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • certolizumab pegol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CJM-112 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • COVA-322 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dimethyl fumarate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • etanercept biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • etanercept biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • etanercept biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GSK-2831781 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ixekizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KM-133 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lunacalcipol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MT-1303 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • namilumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • orilotimod potassium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tildrakizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tofacitinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • XP-23829 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Chronic Plaque Psoriasis - Recent Pipeline Updates
  • Chronic Plaque Psoriasis - Dormant Projects
  • Chronic Plaque Psoriasis - Discontinued Products
  • Chronic Plaque Psoriasis - Product Development Milestones
    • Featured News & Press Releases
      • Jun 08, 2015: Pfizer Announces 12 Presentations Including New Research Data on Tofacitinib for Chronic Plaque Psoriasis and Atopic Dermatitis at World Congress of Dermatology
      • Feb 04, 2015: Pfizer Announces FDA Acceptance For Review Of Supplemental New Drug Application For Oral XELJANZ (tofacitinib citrate) For Adult Patients With Moderate To Severe Chronic Plaque Psoriasis
      • Jul 16, 2014: Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 (Investigational Etanercept Biosimilar) In Chronic Plaque Psoriasis
      • May 23, 2014: Pfizer Announces Detailed Results For Phase 3 OPT Retreatment Study Of Tofacitinib In Adults With Moderate-To-Severe Chronic Plaque Psoriasis
      • Apr 22, 2014: Pfizer Announces Positive Top-Line Results from Two Phase 3 Trials of Tofacitinib in Adults with Moderate-to-Severe Chronic Plaque Psoriasis
      • Mar 22, 2014: Pfizer Announces Detailed Results of OPT Compare Phase 3 Study of Tofacitinib 5 mg and 10 mg Twice Daily Compared to High-Dose ENBREL in Adults with Moderate-to-Severe Chronic Plaque Psoriasis
      • Mar 28, 2012: Lilly's Ixekizumab Met Primary Endpoint In Phase II Study In Patients With Chronic Plaque Psoriasis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Chronic Plaque Psoriasis, H2 2015
  • Number of Products under Development for Chronic Plaque Psoriasis - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Chronic Plaque Psoriasis - Pipeline by AbGenomics International, Inc., H2 2015
  • Chronic Plaque Psoriasis - Pipeline by Almirall, S.A., H2 2015
  • Chronic Plaque Psoriasis - Pipeline by Boehringer Ingelheim GmbH, H2 2015
  • Chronic Plaque Psoriasis - Pipeline by Cellceutix Corporation, H2 2015
  • Chronic Plaque Psoriasis - Pipeline by Coherus BioSciences, Inc., H2 2015
  • Chronic Plaque Psoriasis - Pipeline by Eli Lilly and Company, H2 2015
  • Chronic Plaque Psoriasis - Pipeline by GlaxoSmithKline Plc, H2 2015
  • Chronic Plaque Psoriasis - Pipeline by Johnson & Johnson, H2 2015
  • Chronic Plaque Psoriasis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015
  • Chronic Plaque Psoriasis - Pipeline by Novartis AG, H2 2015
  • Chronic Plaque Psoriasis - Pipeline by OPKO Health, Inc., H2 2015
  • Chronic Plaque Psoriasis - Pipeline by Pfizer Inc., H2 2015
  • Chronic Plaque Psoriasis - Pipeline by Sandoz International GmbH, H2 2015
  • Chronic Plaque Psoriasis - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015
  • Chronic Plaque Psoriasis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015
  • Chronic Plaque Psoriasis - Pipeline by UCB S.A., H2 2015
  • Chronic Plaque Psoriasis - Pipeline by XenoPort, Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Chronic Plaque Psoriasis Therapeutics - Recent Pipeline Updates, H2 2015
  • Chronic Plaque Psoriasis - Dormant Projects, H2 2015
  • Chronic Plaque Psoriasis - Dormant Projects (Contd..1), H2 2015
  • Chronic Plaque Psoriasis - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Chronic Plaque Psoriasis, H2 2015
  • Number of Products under Development for Chronic Plaque Psoriasis - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top